



The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science.

We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era, pioneer innovation, push the frontiers of knowledge, enlist diverse new scientific talent, and lead the drive to new treatments, prevention and cure.

## ONE OF THE MOST TRUSTWORTHY HEALTH ORGANIZATIONS IN THE COUNTRY

The Lupus Research Alliance (LRA) was once again named by *Consumer Reports* as one of the best health organizations to donate to in 2020. This blue-chip recognition is based on ratings by independent watchdog groups like BBB Wise Giving Alliance and CharityWatch.

**We have invested more than \$215 million in lupus research programs** and delivered breakthroughs that are speeding up the development of new treatments and enabling scientists to investigate theories toward prevention and the ultimate goal – a cure.

## UNWAVERING IN THE PURSUIT OF SCIENTIFIC DISCOVERY – INVESTING IN TRAILBLAZING RESEARCH

Despite the uncertainty around COVID-19, the LRA was still able to jumpstart intriguing scientific investigations that hold the promise of making breakthroughs in treatment. The LRA invested almost \$11.5 million in research last year to continue to fund breakthrough projects in lupus.

- Seven world-renowned scientists received \$2.1 million in grants through our **Lupus Innovation Award** grant program, which supports advances in novel hypotheses and/or technologies.
- Our **Lupus Mechanisms** and **Target Awards** granted \$3 million for five pioneering research projects aimed at characterizing lupus disease progression and identifying targets for treatment.
- The **Distinguished Innovator Awards** provided \$2 million to two exceptional scientists who aim to shift the lupus paradigm with bold explorations.
- **Jane Salmon, MD** was the recipient of our **Lupus Insight Prize** of \$100,000, in recognition of her dedication to improving the health of pregnant women with lupus.

### BOARD OF DIRECTORS

Richard K. DeScherer  
*Co-Chairman*  
Ira Akselrad  
*Co-Chairman*  
Brenda Blackmon  
*Secretary*  
Joseph Mauriello  
*Treasurer*  
Bishop Rudy V. Carlton  
Jerome A. Chazen  
Willie Colon  
Thomas O. Daniel, MD  
Jennie L. DeScherer  
Katey Driscoll  
Sir Marc Feldmann FRS  
Moti Ferder  
Joe Germanotta  
David Kies  
Daniel M. LaVecchia  
Louis Lucido  
Molly McCabe  
Nadeem Meghji  
William J. Mulvihill  
Robert Seder, MD  
Daniel J. Wallace,  
MD, FACP, MACR  
Carol Weisman  
William J. Wolfe  
Spencer Zwick

### OFFICERS

Kenneth M. Farber  
*President & CEO*  
Debra Rose  
*Chief Finance & Administrative Officer*  
Teodora Staeva, PhD  
*Chief Scientific Officer*  
Andrea J. O'Neill  
*Executive Director*  
Albert Roy  
*Executive Director, Lupus Therapeutics, LLC*

### SCIENTIFIC ADVISORY BOARD

Gary A. Koretzky, MD, PhD  
*Chair*  
Vivien Bonazzi, PhD  
Mary Collins, PhD  
Mariana Kaplan, MD  
Josef Penninger, MD, PhD  
Robert Plenge, MD, PhD  
David J. Rawlings, MD  
Jane Salmon, MD

ManyOne Can.  
**walk** WITH US  
**TO CURE LUPUS**

## POWER IN NUMBERS

If there is one thing that the Lupus Research Alliance has learned, it's that there is power in numbers, and we need no greater proof than our Walk with Us to Cure Lupus program.

Walkers – passionate about ending lupus – may walk because a family member, friend or colleague has lupus. Or they may walk because they have lupus themselves. The important part is they decided to be part of the solution – even virtually! People around the country were resolute in participating in the LRA Virtual Walk program to ensure better treatments and eventually a cure become a reality for lupus patients around the world. Such passion has generated over \$1 million in 2020. Even more remarkable is the fact that since this grassroots fundraiser began, a cumulative total of over \$41 million has been raised for critical lupus initiatives from these supporters.

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

The following is an overview of the Lupus Research Alliance's income and expenditures for the fiscal year ended December 31, 2020.

### Revenue & Other Support:

Contributions	\$ 41,539,746
Other Support	\$ 4,365,446

**Total Revenue & Other Support: \$45,905,192**

### Program Expenditures:

Research	\$ 15,400,647
Scientific programs	\$ 12,839,966
Public policy	\$ 743,966

**Total Program Expenditures: \$28,984,579**


**Administration Expenditures: \$ 2,264,536 ★**

**Fundraising Expenditures: \$ 2,838,968 ★**

**End of Year Net Asset Balance: \$61,557,055**

\*The LRA's Supporting Services are covered by donations from its Board of Directors.

Because the LRA Board of Directors funds our administrative and fundraising costs, 100% of your contribution to the LRA goes directly to support lupus research programs.



The LRA contracts Lutz and Carr, CPA's as its independent auditor. A complete copy of the audited financial statements of the LRA for the year ended December 31, 2020, together with the independent auditor's report thereon, may be obtained through a written request to the LRA's national office and is also available on the LRA website; lupusresearch.org. The LRA is tax-exempt under 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible to the extent allowed by law.



275 Madison Ave, 10th Floor  
 New York, New York 10016